| Literature DB >> 35790637 |
Neha Benedicta Fernandes1, Raghavendra Udaya Kumar Shenoy1, Mandira Kashi Kajampady1, Cleona E M DCruz2, Rupesh K Shirodkar2, Lalit Kumar3, Ruchi Verma4.
Abstract
Cancer is a most common cause of mortality globally. Available medicines possess severe side effects owing to their non-specific targeting. Hence, there is a need of an alternative in the healthcare system that should have high efficacy with the least side effects, also having the ability to achieve site-specific targeting and be reproducible. This is possible with the help of fullerenes. Fullerenes are having the unique physicochemical and photosensitizer properties. This article discusses the synthesis, functionalization, mechanism, various properties, and applications of C60 fullerenes in the treatment of cancer. The review article also addresses the various factors influencing the activity of fullerenes including the environmental conditions, toxicity profile, and future prospective.Entities:
Keywords: Biocompatibility; Biodegradability; Biosensing; Cancer therapy; Nanomedicine; Nanotechnology; Photodynamic therapy
Mesh:
Substances:
Year: 2022 PMID: 35790637 PMCID: PMC9399030 DOI: 10.1007/s11356-022-21449-7
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 5.190
Physical properties of fullerene (Yadav 2018)
| Sr. no | Properties | Value |
|---|---|---|
| 1 | Density | 1.65 g/cm3 |
| 2 | Refractive index | 2.2 (600 nm) |
| 3 | Melting point | 260 °K |
| 4 | Boiling point | Sublimes at 800 °K |
| 5 | Standard heat of formation | 9.08 K Cal/mol |
| 6 | Resistivity | 1014 Ohms/m |
| 7 | Vapor pressure | 5 × 10−6 torr at room temperature |
| 8 | Thermal conductivity | 0.4 W/mK |
| 9 | Young’s modulus | 14 GPa |
Fig. 1Fullerene as a photosensitizer in photodynamic therapy
Fig. 2Arc discharge method
Fig. 3Laser ablation method
Fig. 4Combustion method
Fig. 5Formation of fullerenol
Fig. 6Formation of 1,2 and 1,4 amine substituted fullerene
Surface modified fullerenes for clinical applications
| Sr. no | Drug/carriers | Method | Outcome | Reference |
|---|---|---|---|---|
| 1 | Dihydroartemisinin | Dihydroartemisinin functionalization on C60 using 1, 3- Dipolar cycloaddition of azomethine ylide | Functionalizing C60 with dihydroartemisinin improved the aqueous solubility. Furthermore, nonlinear optical properties are considerably improved | Fouejio et al. |
| 2 | R-thiazolidinethione (R: propyl, butyl, hexyl, phenyl) | Thiolation of R-thiazolidinethione on C60 fullerene | Functionalizing C60with thiazolidinethione increases the dipole moment of the formed complexes allowing higher solubility in polar solvents and improves (improving) the stability of the formed structures | Ferreira et al. |
| 3 | Dendrofullerene (DF-1) | Dendro[60]fullerene is obtained via nucleophilic cyclopropanation of C60 with a 2nd generation bis(polyamide)-malonate dendrimer and deprotection of the terminal t-butyl groups | Radioprotection | Brettreich and Hirsch |
| 4 | Fullerene–paclitaxel | The asymmetrical malonate obtained by treating tert-butyl N-(3-hydroxypropyl)carbamate with ethylmalonyl chloride was used to begin the synthesis of the C60-paclitaxel conjugate. Bingel-Hirsh addition to C60, followed by amino group deprotection was carried out | Cancer therapy | Zakharian et al. |
| 5 | Fullerene-doped liposomes or lipid-membrane–incorporated C60 fullerenes (LMIC) | Fullerene exchange method from a γ-cyclodextrin (γ-CD) cavity to vesicles | Photodynamic cancer therapy | Ikeda et al. |
| 6 | Fullerene-liposomes | Amphiphilic liposomal malonylfullerene (ALMF) and phospholipids co-assemble and form bilayer vesicles | Antioxidant property increased loading capacity | Lens et al. |
| 7 | Fullerene vesicles | A water-soluble fullerene vesicle is generated where the R-group is substituted with C6H5, a phenyl (penta-) substituted fullerene cyclopentadienide (Ph5C60 K or PhK) and attains hydrophobic capabilities | Oxidative stress reduction | Maeda et al. |
| 8 | Gadofullerenes | Phase transfer catalyzed (catalyzed) hydroxylation of Gd@C82 | MRI contrast agents | Bolskar et al. Tóth et al. Sitharaman et al. |
| 9 | Hydrophilic or cationic fullerenes | Functionalization of fullerenes with monocationic and tricationic dimethylpyrrolidinium | Photodynamic cancer therapy | Mroz et al. |
| 10 | Human serum albumin-fullerene Fullerene hexaadducts PEG-modified fullerene | Complexation of HSA-C3 isomer with tris-malonic acid [C60] fullerene Pyropheophorbide- Water-insoluble fullerene (C60) conjugated with poly(ethylene glycol) (PEG) | Photodynamic cancer therapy Photodynamic cancer therapy Photodynamic cancer therapy | Belgorodsky et al. Rancan et al. Tabata et al. |
| 11 | Fullerene polyamine (tetraamino fullerene) | Aminofullerene; tetrapiperidinofullerne is synthesized from fullerene, piperazine, and molecular oxygen | Gene delivery, transfection | Nakamura et al. Isobe et al. |
| 12 | Amino-fullerene adducts | Amino-C60 adducts were prepared and functionalized with octa-amino and dodeca-amino groups by Hirsch-Bingel reaction | Non-viral gene delivery | Sitharaman et al. |
| 13 | C60–cisplatin nanocomplex | Formation of non-covalent, entropically driven nanocomplexes between Cisplatin and C60 fullerene in physiological solution (i.e., the adsorption of Cis in C60 fullerene clusters) | Act as drug delivery carriers, mixture does not influence genotoxic Cisplatin activity and reduces the factions of necrotic cells | Prylutska et al. |
| 14 | C60-berberine nanocomplex | Non-covalent complexation of herbal alkaloid Berberine with C60 fullerene | Act as drug delivery carriers, inhibiting the proliferation of CCRF-CEM cells | Grebinyk et al. |
Fig. 7Depicts the activity of Gd@C82(OH)22 in cancer therapy acting as a metastasis inhibitor, ROS scavenger, cell cycle regulator, cellular immunity activator, and an angiogenesis suppressor
Surface functionalized fullerenes to target various cancer pathways
| Primary molecule | Active therapeutic molecule | Role | Mechanism | Reference |
|---|---|---|---|---|
| Fullerene C-60/fullerene C-82 | C60 (OH)22 | Targets cancer stem cells | Inhibition of biological communication stem cells and tumor cells | (Nie et al. |
| Gd@C82 (OH)22 | Targets cancer stem cells | Reversal of phenotype of EMT in cancer cells | (Liu et al. | |
| Gd@C82 (OH)22 | Inhibits angiogenesis | Downregulation of 10 proangiogenic factors in mice model | (Meng et al. | |
| C60 (OH)20 | Inhibits angiogenesis | Downregulation of TNF-α, PDGF, and VEGF by 20–40% in EMT-6 tumor metastasis model | (Jiao et al. | |
| β-Alanine–Gd@C82 (OH)22 | Inhibits Angiogenesis | Radiofrequency-mediated destruction of tumor vasculature | (Zhou et al. | |
| Gd@C82 (OH)22 | Reactive oxygen species | Decrease in oxidative stress parameters in mice with H22 hepatoma | (Wang et al. | |
| Gd@C82 (OH)22, C60(OH)22 | Reactive oxygen species | ROS scavenging capability as; Gd@ C82(OH)22 > C60(OH)22 > C60(C(COOH)2)2 | (Yin et al. | |
| Gd@C82 (OH)22 | Extracellular matrix | Decreased activity of MMP-2 and MMP-9 in tumor associated macrophages | (Meng et al. | |
| Iron oxide nanoparticles on PEGylated fullerene (C60) | Photodynamic therapy | Marked cytotoxicity in vitro and in vivo upon 532 nm light irradiation | (Shi et al. | |
| GO–fullerene hybrid | Photothermal and photodynamic therapy | High thermal ablation of cancer cells with increase in ROS production | (Li et al. |
List of fullerene patents for cancer therapy
| SL. no | Patent no | Title | Description | Reference |
|---|---|---|---|---|
| 1 | JP2005053904A | Fullerene and anticancer therapeutic agent | The current invention pertains to an anticancer therapeutic drug for use in neutron capture treatment (NCT), which is widely anticipated in the medical industry due to cancer tissue’s specific therapeutic capabilities | (Kasama et al. |
| 2 | KR101479858B1 | Fullerene nanogel prodrug for anticancer therapy | The current invention pertains to photodynamic treatment, namely the utilization of acid-activated fullerene nanogel prodrugs as cancer therapeutic agents and photosensitivity prodrugs. The current invention pertains to a new molecule for use in photodynamic treatment for malignant tumors that generates much better tumor selectivity and singlet oxygen than standard porphyrin-based photosensitizers, as well as a method for making it | (이은성 et al. |
| 3 | WO2007033578A1 | Metallo-fullerenols and its application in preparation of medicines for inhibiting the growth of tumor | The innovation concerns a new nanomaterial and its use in biomedicine. It concerns a metal fullerene nanoparticle with the formula M@C 2 m (OH) × and its usage in the creation of a tumor-inhibiting medicament, where M is chosen from the group of rare earth metals such as Gd and La | (Zhao et al. |
| 4 | WO2018064963A1 | Use of fullerene structure in preparation of medicament for treating tumor | The use of a fullerene structure containing at least one active ingredient selected from the group consisting of an oil-soluble hollow fullerene, an oil-soluble metallofullerene, a composition of the oil-soluble hollow fullerene and the oil-soluble metallofullerene, a combination of the water-soluble hollow fullerene and the water-soluble metallofullerene, a pharmaceutically acceptable ester of the water-soluble hollow fuller A pharmaceutical composition, a health care product, or a health food including the fullerene structure is also provided. A technique for producing the fullerene structure is also presented |
(王春儒 et al. |
| 5 | CN107913289A | Application of the water-soluble fullerene structure in the medicine for preparing treatment tumor | The invention proposes a method of using a water-soluble fullerene structure in medicine to prepare therapy for tumors. The water-soluble fullerene structure contains the following: empty fullerene that is water-soluble and contains at least one pharmaceutically relevant salt or ester. The pharmaceutical is compatible with the human body, has minimal toxicity, is effective at suppressing tumors, and has a favorable therapy impact on tumors | 王春儒 et al. ( |